JRC News

  1. 4 May 2016

    European experts in alternative approaches to animal testing promote current and future collaborations with partners in Brazil.

  2. 17 Mar 2016

    The use of nanotechnology in healthcare promises new diagnostic opportunities and innovative therapeutic concepts that may help to tackle major medical challenges such as cancer, neurodegenerative diseases and antimicrobial resistance.


    However, the manufacturing process of nanomedicines is sophisticated, and quality inconsistencies between batches must be carefully monitored before clinical applications can be considered. Furthermore, safety concerns related to the use of nanomaterials must be addressed as early as possible during product development.

  3. 8 Feb 2016

    JRC scientists contributed to the evaluation of the method performance related to the quantification of Alzheimer's biomarkers. The study revealed the importance of developing a certified reference material, which is currently in progress at the JRC-Institute for Reference Materials and Measurements (IRMM).

  4. 29 Jan 2016

    JRC scientists, in collaboration with partners of a European research project, addressed measurement issues that impact on the monitoring of harmful microorganisms. They conclude that innovative and standardised methods have the potential for better measurement results in supporting clinicians and patients' health status.

  5. 18 Jan 2016

    In close collaboration with partners of the European project EQuATox (establishment of quality assurance for the detection of biological toxins of potential bioterrorism risk) - coordinated by the German Robert Koch Institute – JRC scientists supported analytical work on toxins derived e.g. from Clostridium (C.) botulinum. The EQuATox consortium characterised six recombinant Botulinum neurotoxins (BoNTs) and assessed the detection capability of expert laboratories through a proficiency test.

  6. 5 Jan 2016

    The plenary of the European Commission Initiative on Breast Cancer (ECIBC) entitled 'Improving breast cancer screening, diagnosis and care in Europe' took place in Baveno, Italy on 9-11 December 2015. The plenary focused on improving quality, multidisciplinarity and continuity of care as well as identifying measures for clearer communication. This event marked an important step towards harmonised quality standards for breast cancer services, including screening.

  7. 10 Dec 2015

    The emergence of antimicrobial resistance is a threat which is increasingly causing serious health problems to EU citizens and there is a pressing need to develop novel classes of antimicrobial agents. In the search for a solution to this problem, antimicrobial peptides (molecules consisting of 2 or more amino acids) are being recognized as promising candidates in the fight against bacterial pathogens.

  8. 17 Nov 2015

    Members of the International Cooperation on Alternative Test Methods attended a two-day meeting hosted by the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM).

  9. 14 Oct 2015

    Progressing alternatives to animal testing through better understanding of toxicological processes, wider application of new methodologies and tools, and greater interaction between different disciplines and communities.

  10. 10 Jul 2015

    JRC scientists have characterised and certified the mass concentration of the cancer marker beta-2-microglobulin as an additional parameter in the certified reference material for proteins in human serum. This work was done in close collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) for the standardisation of measurements of proteins.